SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARRIS - Another partner
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: CYBERKEN who wrote (327)12/24/1997 11:05:00 AM
From: John Metcalf  Read Replies (1) of 353
 
The patent situation is not clear to me. There is a small company called Prototek which holds some cathepsin patents. We know about SKB (thanks Miljenko). HGSI has a Cathepsin O patent, including antibodies,, antagonists, and inhibitors thereof.

I've seen no information on a Delta-designed Cathepsin K inhib. SKB's PNAS article indicated that structure-based design was used in the evolution of their inhibs, but they don't have Delta (unless they were able to used something from the ARRS antiviral partnership).

Though I appreciate Miljenko's comments, I don't assume that publishing this article means a significant lead in the real world. If ARRS has done similar work, they would not have published due to the trade secret nature of Delta (until recently). Now that Delta is patented, they need to publish if they want to command respect for the technology.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News